Although people who recover from COVID-19 usually gain some immune defenses against reinfection, they get additional protection from vaccines, especially against severe disease, according to two studies published on March 31 in The Lancet Infectious Diseases. Additionally, two gold-standard trials published in The New England Journal of Medicine on March 30 help settle questions about two controversial therapies touted by many early in the pandemic with decidedly mixed results – failure for the antiparasite drug ivermectin and success for antibody-rich blood plasma from COVID-19 survivors.
Malaysian researchers found that treatment with the anti-parasite drug ivermectin did not prevent patients with COVID-19 from becoming severely ill in a randomized clinical trial published in the JAMA Internal Medicine journal on February 18.
The U.S. Centers for Disease Control and Prevention pointed out that people in the United States who have received their booster shots are 97 times less likely to die of COVID-19 than the unvaccinated, and people with full doses but no boosters are 14 times less likely to die of the disease.
Aside from vaccines, the advent of several effective COVID-19 antiviral therapies, including Pfizer’s Paxlovid, provides hope for ending the pandemic. Details about the U.S. government’s contract with Pfizer for 10 million doses of Paxlovid are emerging, with some unusual elements.
As global corporations reach deeper into every part of our lives, marketing is evolving into something unrecognizable. According to Michael Farmer, in the Mad Men Era of the 1960s and 70s, your average creative agency was responsible for roughly 350 deliverables a year—whether they were print copy, radio scripts, or billboard headlines. Today? The average number of deliverables per creative per year is over 10,000.
“You are not a horse. You are not a cow. Seriously, y’all. Stop it.” This is the Food and Drug Administration’s (FDA) tweeted advice to Americans seeking out alternative, unapproved treatments for Covid-19.
The University of Oxford is testing the anti-parasitic drug ivermectin as a possible treatment for Covid-19, as part of a British government-backed study that aims to aid recoveries in non-hospital settings.